research
The Treatment Response Left an Immune Signature
Exploratory data tied IL-15, IL-7 and B-cell signaling to response patterns after rapid-acting depression therapies.
Summary
Exploratory data tied IL-15, IL-7 and B-cell signaling to response patterns after rapid-acting depression therapies.
MD Anderson researchers found that participants who responded to rapid-acting antidepressant therapies entered treatment with lower IL-15 activity and higher B-cell signaling, with some patterns reversing afterward. The Molecular Psychiatry analysis points to immune pathways that may help explain variable responses to ketamine and psychedelic-assisted interventions. The signals are exploratory biomarkers and require larger prospective validation.
Why it matters
Exploratory data tied IL-15, IL-7 and B-cell signaling to response patterns after rapid-acting depression therapies.
Limits and context
- The signals are exploratory biomarkers and require larger prospective validation.
Key claims
Exploratory data tied IL-15, IL-7 and B-cell signaling to response patterns after rapid-acting depression therapies.
Qualification: The signals are exploratory biomarkers and require larger prospective validation.
Evidence: source-2026-07-31-008
Sources
- MD Anderson via Newswise: Immune signals and rapid antidepressant responseThe University of Texas MD Anderson Cancer Center · official announcement
Corrections
No corrections have been recorded for this story.